Skip to main content

At Home Care

Home Nursing, Elderly Care & Patient Care Services in Gurgaon | AtHomeCare
AtHomeCare Logo
ATHOMECARE™ KEEPING YOU WELL AT HOME
24×7 Medical Support
+91 99108 23218
Book Consultation

Why is AtHomeCare the Best Home Care in Gurgaon?

AtHomeCare India is the only truly integrated home healthcare provider in Gurgaon, offering all critical services under one roof—without outsourcing.

Lambert-Eaton Myasthenic Syndrome Case Study in Gurgaon

Lambert-Eaton Myasthenic Syndrome Case Study in Gurgaon | AtHomeCare
Clinical Case Study · Neuromuscular Home Care

Lambert-Eaton Myasthenic Syndrome With Leg Weakness and Walking Difficulties

A clinically documented Lambert-Eaton Myasthenic Syndrome (LEMS) case study from Gurgaon, Haryana, showing how structured home healthcare was used to manage progressive leg weakness, reduce fall risk, coordinate medication and support daily living. The patient is fictional and the journey is illustrative for education of patients, caregivers and clinicians.

Patient
Mr. Siddharth Khanna
Age & Gender
52 years · Male
Location
Gurgaon, Haryana
Primary Condition
Lambert-Eaton Myasthenic Syndrome
Care Focus
Mobility, fall prevention, medication coordination, safety monitoring
Duration of Home Support
Ongoing (illustrative 12-week coordination period)
Case Type
Illustrative / educational (fictional patient)
Clinical Outcome
Improved coordination, lower fall risk, stable routine (illustrative)
Note: This is an illustrative fictional case study for education. It does not describe a guaranteed response to treatment and is not a substitute for individual medical advice.

1Patient Background

Medical history, lifestyle, risk factors, family situation and baseline function.

Mr. Siddharth Khanna is a 52-year-old man who lives in Gurgaon with his family. Before his symptoms began, he managed his household and community activities independently and did not require assistance with walking, bathing or dressing. His baseline function was that of an active middle-aged adult, which is important context because the changes he later noticed were a clear departure from his usual ability rather than a gradual decline he had accepted over years.

The problem started with slowly increasing weakness in his legs. Standing up from a low chair, climbing stairs and walking longer distances gradually became harder. At first the family linked these changes to general physical weakness or ageing, because the onset was slow and there was no single dramatic event. The shift in thinking came when the leg weakness continued and he also noticed a dry mouth and other small changes in everyday functioning. These autonomic symptoms, sitting alongside muscle weakness, suggested the problem was neurological rather than a simple loss of fitness, and the family arranged a neurological evaluation.

Doctor Explanation

Proximal leg weakness that is slowly progressive, paired with autonomic features such as dry mouth and reduced reflexes, is a recognised pattern for disorders of the neuromuscular junction. The combination is what separates LEMS from ordinary age-related weakness, where reflexes and autonomic function are usually preserved. Recognising this pattern early is what leads to the correct investigations.

Documented baseline and risk factors

  • Baseline function: independent mobility, self-care and household participation before symptom onset.
  • Presenting concerns: progressive proximal leg weakness, difficulty standing from a seated position, difficulty climbing stairs, reduced walking endurance, fatigue and dry mouth.
  • Risk factors identified: age 52, fluctuating leg strength, postural dizziness on standing, and an initially low index of suspicion at home that delayed fuller evaluation.
  • Family situation: supported by family members who observed the changes, sought neurological assessment and remained closely involved in daily care decisions.
Not documented in available records: prior comorbidities, long-term medication list, occupation, detailed family medical history, and prior hospitalisations. These were not provided for this illustrative case and are therefore not described, in line with the principle that only documented information should be reported.

2Clinical Diagnosis

Diagnosis, clinical and neurological findings, investigations and important observations.

Diagnosis

The evaluation led to a diagnosis of Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder in which communication between nerves and muscles is impaired. LEMS is autoimmune in nature. In most patients the immune system produces antibodies against presynaptic voltage-gated calcium channels at the neuromuscular junction. These channels normally allow calcium to enter the nerve ending so that acetylcholine, the chemical messenger that activates muscle, can be released. When the channels are targeted by antibodies, less acetylcholine is released, the muscle receives a weaker signal, and weakness results.

LEMS can occur on its own as an autoimmune condition, or it can occur in association with certain cancers, particularly small-cell lung cancer. Because of this association, evaluation for an underlying malignancy is considered an essential part of the diagnostic workup and ongoing follow-up, not an optional add-on. Distinguishing paraneoplastic LEMS from non-paraneoplastic LEMS changes both prognosis and the priority of cancer treatment in the overall plan.

Clinical and neurological findings documented

  • Weakness in the hips and thighs (proximal leg weakness).
  • Difficulty standing up from a seated position.
  • Difficulty climbing stairs.
  • Reduced walking endurance.
  • Dry mouth.
  • Constipation.
  • Reduced sweating.
  • Dizziness on standing, related to blood pressure changes.
  • Reduced reflexes on neurological examination.
Doctor Explanation

A useful clinical feature of LEMS is that weakness may briefly improve after a short period of repeated muscle activation, because repeated nerve stimulation can transiently build up enough acetylcholine release to strengthen the muscle response. Reduced or absent reflexes that briefly return after sustained contraction are another characteristic clue. These features help clinicians separate LEMS from myasthenia gravis, where weakness typically worsens with repeated use and reflexes are usually normal.

Investigations performed

The neurological assessment included a structured set of tests designed to confirm the site of the problem and to screen for an associated cancer:

  • Neurological examination with assessment of muscle strength and reflexes.
  • Nerve conduction studies and electromyography (EMG), which assess how well electrical signals travel from nerve to muscle.
  • Blood testing for relevant antibodies associated with LEMS.
  • Evaluation for an underlying malignancy, including chest imaging as clinically indicated.
Not documented in available records: the specific anti-VGCC antibody titre, the exact nerve conduction values (such as compound muscle action potential amplitudes and the incremental response on repetitive stimulation), and the formal report of chest imaging. The investigations were documented as performed, but their quantitative results were not shared for this illustrative case and are therefore not presented.

Why these investigations were chosen

Nerve conduction studies and EMG were chosen because they directly test whether the failure is at the nerve-to-muscle junction rather than in the muscle itself or the nerve fibre. In LEMS the characteristic finding is a low resting muscle response that increases after brief exercise or rapid stimulation, which objectively confirms impaired acetylcholine release. Antibody testing was chosen to support the clinical and electrical evidence and to help confirm an immune-mediated mechanism. Chest imaging and malignancy screening were chosen because a meaningful proportion of LEMS cases are paraneoplastic, and finding an underlying small-cell lung cancer early can change both the cancer outlook and the neurological course.

3Hospital Treatment

Hospital course, procedures, medication plan, monitoring and discharge status.

Mr. Khanna’s assessment was carried out through a neurology service on an outpatient basis. There was no documented intensive-care admission, which is consistent with the clinical picture: LEMS at this stage required detailed diagnostic evaluation and a structured treatment plan rather than acute critical-care support. The focus of the hospital-phase work was confirmation of the diagnosis, completion of malignancy screening and agreement on a treatment direction.

Procedures

  • Nerve conduction studies and electromyography to localise the defect to the neuromuscular junction.
  • Blood sampling for LEMS-related antibody testing.
  • Chest imaging for paraneoplastic screening, as clinically indicated.

Medication plan discussed

The treating specialist explained that treatment may include medicines that improve neuromuscular transmission and therapies that modify the immune response. Medicines such as amifampridine and pyridostigmine may be considered by specialists, along with immune-modifying treatments where appropriate. Amifampridine works by improving the release of acetylcholine from the nerve ending, which can ease weakness. Pyridostigmine prolongs the action of acetylcholine at the muscle. Immune-modifying therapies aim to reduce the antibody activity driving the condition. If an associated cancer is identified, its treatment is also an important part of management, because treating the tumour can sometimes improve the neurological symptoms.

Important: Medication selection and dosing in LEMS require individual medical supervision. Medicines such as amifampridine and pyridostigmine are specialist prescriptions with specific dosing, timing and monitoring requirements. They must never be started, stopped or adjusted without the treating neurologist’s instruction.

Monitoring

Planned monitoring included regular neurology review to track muscle strength and autonomic symptoms, ongoing communication regarding malignancy screening results, and assessment of tolerance to any prescribed medication. The family was asked to report new swallowing or breathing difficulty, repeated falls, fainting or rapid worsening without waiting for the next scheduled appointment.

Discharge status

Mr. Khanna returned home with a treatment direction agreed with his neurologist and a clear need for structured support at home. He was medically stable for home care but had identifiable risks: proximal leg weakness with falls during transfers and stairs, postural dizziness, fatigue, and a medication routine that needed careful coordination. This combination defined the goals of the home healthcare plan that followed.

4Why Home Healthcare Was Needed

The clinical reasoning behind structured home support.

Home healthcare was appropriate because the risks created by LEMS are mostly risks of daily living rather than risks that require a hospital bed. Once the diagnosis was confirmed and a treatment direction agreed, the patient was medically stable enough to be at home. What he needed was a safe environment, supervised mobility, reliable medication coordination and a family that understood the warning signs. These are exactly the problems that professional home healthcare is designed to solve, and they cannot be solved by a single hospital visit or a prescription alone.

The specific clinical reasons

  • Fall risk during transfers and stairs: proximal leg weakness makes standing from a chair and climbing stairs unreliable, and postural dizziness adds a second layer of risk. Supervised transfers and environmental changes directly reduce this risk.
  • Fluctuating weakness: strength can vary through the day, so the care plan had to allow rest periods and avoid walking alone during weaker periods.
  • Medication coordination: LEMS treatment may involve symptomatic medicines and immune-modifying therapy taken on precise schedules, with side effects that must be watched. A structured medication record prevents missed or doubled doses.
  • Autonomic symptom monitoring: dry mouth, constipation, reduced sweating and orthostatic dizziness need day-to-day tracking, because changes can signal worsening or treatment intolerance.
  • Swallowing and breathing awareness: although less common than leg weakness, bulbar or respiratory involvement must be recognised early and treated as urgent if it appears.
  • Family education: relatives had to understand that LEMS is an immune-mediated neurological condition, not simple ageing, so they could respond correctly to changes.
  • Specialist follow-up coordination: neurology review and malignancy screening appointments had to be tracked and communicated between teams.
Clinical scenario: A patient with confirmed LEMS, stable for home, but with proximal weakness and postural dizziness living in a standard Gurgaon apartment with stairs and low seating, is a textbook indication for structured home support. The aim is not to replace the neurologist. It is to make the home safe enough that the neurologist’s plan can actually be followed every day without a fall or a medication error undoing the progress.

For families exploring this kind of support, AtHomeCare’s home nursing services and patient care services provide the supervised daily layer that sits underneath the specialist’s medical plan. Where a higher level of observation is temporarily required, ICU at home in Gurgaon can bridge the gap, although it was not needed in this case.

5Home Care Plan by AtHomeCare

Every intervention, with the clinical reasoning behind it.

The home care plan was built around seven domains drawn from the initial home-care assessment. Each domain answers a specific risk created by LEMS, and each was paired with an intervention the family could realistically sustain. The plan was deliberately modest in its promises: it aimed for safety, coordination and comfort, not for a cure.

1. Mobility and Fall Prevention

Proximal leg weakness and postural dizziness make standing, stair use and walking the highest-risk activities of the day. The plan began with a physiotherapist assessing the need for a walking aid and the correct seat height, because the wrong aid or the wrong chair can increase falls rather than reduce them. Stable chairs with armrests, handrails where steps are used, and keeping frequently used belongings within easy reach reduce the number of unnecessary transfers. Assistance during transfers was provided when weakness or dizziness was significant, and walking alone was avoided during those periods.

Fall prevention is one of the most evidence-based parts of home care for neuromuscular conditions. Families can read more about practical environmental changes in the guide to home modifications and fall prevention for Gurgaon seniors and the broader comprehensive fall prevention guide. A physiotherapist-led mobility plan, such as the approach described for daily movement plans, sets a safe activity rhythm.

2. Daily Living Assistance

Fatigue and reduced endurance limit how much can be done before rest is needed. The plan provided help with bathing and dressing when required, seated options for activities that normally need prolonged standing, and a way of organising household tasks into smaller, manageable steps with rest between them. An equally important principle was keeping Mr. Khanna involved in the activities he could safely perform, because unnecessary dependence can accelerate loss of function and affect morale. A trained patient care taker (GDA) or reliable patient attendant in Gurgaon typically delivers this layer of support, supervised by nursing where needed.

3. Medication Coordination

The plan required a clear written record of every prescribed medicine, the neurologist’s schedule, and a simple system for monitoring side effects. LEMS medicines such as amifampridine depend on correct timing and dosing for their effect, and immune-modifying therapy brings its own monitoring requirements. The family was instructed never to change or stop prescribed medication independently and to report any change in symptoms or treatment tolerance to the treating doctor. Practical guidance on safe medication handling at home is covered in the resource on medication safety in elderly home care and the medication management for seniors service, supported by compounder-led medication management.

Medication safety rule: never adjust amifampridine, pyridostigmine or immune-modifying therapy without the neurologist. Sudden changes can cause weakness to worsen or trigger side effects that mimic a flare of the disease itself.

4. Monitoring Autonomic Symptoms

Autonomic involvement in LEMS is easy to overlook but affects comfort and safety every day. The plan tracked dry mouth and constipation, maintained hydration according to medical advice, and asked the family to discuss persistent dizziness with the treating doctor. Episodes of fainting or unusual blood pressure changes were to be recorded and reported. A bowel-management plan was followed where prescribed, because constipation in LEMS is often under-managed and can become a serious daily problem.

5. Respiratory and Swallowing Awareness

Although respiratory failure is less common in LEMS than in some other neuromuscular disorders, the plan treated new swallowing or breathing difficulty as a warning sign. The family was asked to report new swallowing difficulty, to watch for coughing or choking during meals, and to seek assessment for any new breathing problem. Sudden or severe breathing difficulty was treated as an emergency. Background on managing breathing issues at home is available in the respiratory therapy resource.

6. Cancer Screening and Specialist Follow-Up

Because LEMS can be paraneoplastic, attending recommended screening appointments and following the medical team’s plan for repeat imaging was treated as part of care, not a separate task. The plan maintained communication between neurology and oncology teams if cancer was identified, and kept records of test results and treatment discussions in one place so that no follow-up slipped.

7. Emotional and Family Support

The plan explained the condition and its changing symptoms to the family, encouraged Mr. Khanna to say when he felt tired or unsafe, and maintained social and recreational participation within his abilities. Emotional support during investigations and treatment was treated as part of the plan, because anxiety about an unpredictable, rare disease can itself reduce activity and worsen function. Choosing a caregiver who understands this balance matters, and the guide on choosing the right home caregiver in Gurgaon outlines what families should look for.

Clinical reasoning

Each domain maps to a documented LEMS feature: mobility and fall prevention map to proximal weakness; daily living assistance maps to fatigue; medication coordination maps to a precise pharmacological plan; autonomic monitoring maps to dry mouth, constipation and postural dizziness; respiratory and swallowing awareness map to the rare but serious bulbar or respiratory risk; cancer screening maps to the paraneoplastic association; and family support maps to the need for accurate recognition of a fluctuating, unfamiliar condition. Nothing in the plan is decorative. Every intervention exists because the disease creates that specific risk.

6Coordinated Home Support Timeline

An illustrative timeline of how structured home support was introduced and sustained.

The timeline below describes how the home care plan was implemented over the first weeks and months. It is an illustrative reconstruction based on the documented care plan and the family’s follow-up experience. It describes improved care coordination and safety, not a guaranteed response to treatment. Clinical progress in LEMS varies between individuals and depends on the underlying cause, the treatment chosen by the neurologist and the response to that treatment.

Day 1
Home assessment and baseline safety
Clinical progress: medically stable for home; baseline mobility, autonomic symptoms and fall risk documented. Care interventions: home safety walkthrough, medication list collected, high-risk transfer points (low chairs, stairs, bathroom) identified. Doctor review: the neurologist’s plan and warning signs were reviewed with the family. Patient response: engaged with the assessment and expressed relief at having a clear structure. Family observations: recognised that the earlier assumption of age-related weakness had been incorrect.
Day 3
Mobility aid and seating review
Care interventions: physiotherapist assessed the need for a walking aid and correct seat height; stable chairs with armrests placed; handrails checked near steps. Clinical progress: safer sit-to-stand technique taught and practised. Patient response: began using supervised transfers for standing and stair use. Family observations: noted that standing from a higher, stable chair was markedly easier.
Week 1
Daily routine and medication record established
Care interventions: daily schedule adopted; written medication record live; rest periods built in between demanding tasks. Clinical progress: fewer near-falls during transfers with supervision and pacing. Doctor review: tolerance to any prescribed medication checked; side-effect monitoring begun. Family observations: more confident with the morning routine and medicine timing.
Week 2
Family education and autonomic monitoring
Care interventions: family trained on warning signs; dry mouth and constipation tracking started; hydration plan and bowel-management routine followed. Clinical progress: postural dizziness managed with a slow stand-up technique and assisted transfers. Patient response: reported that sipping water through the day reduced dry-mouth discomfort. Family observations: began keeping a simple symptom log to share at the next review.
Week 4
Specialist follow-up and screening coordination
Doctor review: neurology follow-up attended; malignancy screening status reviewed; medication adjusted only by the neurologist where indicated. Clinical progress: walking endurance modestly improved with rest pacing and the walking aid (illustrative). Care interventions: records of test results and discussions consolidated in one file. Family observations: confident in recognising red-flag symptoms and knowing when to call.
Month 2
Coordination between teams maintained
Care interventions: communication between neurology and oncology teams (where screening was ongoing) maintained; no follow-up appointment missed. Clinical progress: stable, with no falls recorded and autonomic symptoms kept manageable. Patient response: increased safe participation in household activities within his endurance limit. Family observations: the routine began to feel sustainable rather than crisis-driven.
Month 3
Confidence and an ongoing plan
Clinical progress: improved confidence in daily activities and transfers; continued monitoring of weakness, autonomic symptoms and treatment tolerance. Care interventions: long-term plan kept in place: fall prevention, medication coordination, autonomic monitoring, swallowing and breathing awareness, and malignancy surveillance. Patient response: reported feeling safer and more in control of his day. Family observations: able to manage the routine with structured support and to recognise when to escalate.
Outcome framing: The follow-up describes better care coordination, reduced fall risk and a stable, sustainable routine. It does not claim that the underlying disease was cured. Strength in LEMS can fluctuate, and long-term outcomes depend on whether the condition is paraneoplastic and on the individual response to specialist treatment.

7Clinical Evidence

Structured tables built only from documented findings. Quantitative values that were not shared for this case are marked as not documented.

The tables below summarise what was documented for this case. Where a value was not recorded in the information shared, the cell is explicitly marked rather than filled with an assumed number. This follows a simple clinical principle: only reported data should appear in a clinical summary.

Table 1. Documented clinical findings at assessment
FindingDocumented
Proximal leg weakness (hips and thighs)Yes
Difficulty standing from a seated positionYes
Difficulty climbing stairsYes
Reduced walking enduranceYes
Dry mouthYes
ConstipationYes
Reduced sweatingYes
Postural dizziness on standingYes
Reduced reflexes on neurological examinationYes
Table 2. Investigations performed and documentation status
InvestigationPurposeResult documented?
Neurological examination (strength and reflexes)Clinical characterisation of weakness and reflexesFindings documented qualitatively
Nerve conduction studies and electromyographyLocalise the defect to the neuromuscular junctionPerformed; quantitative values not documented
Blood testing for LEMS-related antibodiesConfirm an immune-mediated mechanismPerformed; antibody titre not documented
Chest imaging (as clinically indicated)Paraneoplastic screeningPerformed as indicated; formal report not documented
Table 3. Daily living impact documented for this patient
ChallengeImpact on daily life
Proximal leg weaknessDifficulty standing from chairs
Reduced walking enduranceTrouble walking longer distances
Poor balanceIncreased risk of falls
Dry mouthDiscomfort while speaking and eating
ConstipationDisruption of normal daily routine
Postural dizzinessDifficulty standing safely
FatigueReduced participation in household activities
Table 4. Medicines and therapies that may be considered by the specialist
Medicine or therapy classRole in LEMSNotes
AmifampridineImproves acetylcholine release from the nerve endingSymptomatic; specialist dosing required
PyridostigmineProlongs the action of acetylcholine at the muscleLess effective than in myasthenia gravis; may be combined with amifampridine
Immune-modifying therapyReduces the antibody activity driving the diseaseUsed where appropriate, under specialist supervision
Treatment of associated cancer (if identified)May improve neurological symptomsCoordinated between neurology and oncology
Prescription note: The final prescription, doses and schedule were to be individualised by the treating neurologist. Specific medicines, doses and dates are not detailed in the records shared for this illustrative case and are not presented here.
Table 5. Example daily support schedule followed at home
TimeActivity
7:00 AMMorning routine with assistance if needed
8:00 AMBreakfast and prescribed medication
9:00 AMShort, comfortable daily activities
10:30 AMRest
12:30 PMLunch
1:30 PMRelaxation
3:00 PMTherapist-approved mobility activities
4:00 PMFamily interaction or light recreation
6:00 PMRest and personal activities
7:30 PMDinner
9:00 PMMedication review and bedtime routine
Table 6. Equipment and home adaptations in place
AdaptationPurpose
Walking aid (if recommended)Support balance and gait
Stable chairs with armrestsSafer sit-to-stand transfers
Bathroom grab barsReduce fall risk in wet areas
Non-slip flooringReduce slipping
Shower chair (if needed)Seated bathing safety
Handrails near stepsStair safety
Organised medication storagePrevent dosing errors
Clear walking pathwaysRemove trip hazards
Table 7. Quantitative monitoring and documentation status
ParameterDocumentation status
Blood pressure readingsNot documented in available records
Blood sugarNot documented in available records
WeightNot documented in available records
Pain scoreNot documented (pain is not a primary feature of LEMS and was not reported)
Detailed blood investigation valuesNot documented in available records
Imaging measurementsNot documented in available records
Why some tables show “not documented”: No quantitative vital-sign logs, laboratory values, weights or imaging measurements were included in the information shared for this illustrative case. Rather than estimate plausible numbers, the cells are marked as not documented. In a real patient record these tables would be populated with the actual measured values from the discharge summary, laboratory reports and monitoring charts.

8Medical Authority

Author credentials and space reserved for the treating doctor’s comments.

Dr. Ekta Fageriya, MBBS, Geriatric Medicine physician at AtHomeCare

Dr. Ekta Fageriya, MBBS

RMC Registration No. 44780

Specialization
Geriatric Medicine
Clinical Experience
7 Years
Role
Clinical author and reviewer for this case study

9Supporting Clinical Documents

The documentation that supports a LEMS care plan.

Detailed copies of the documents below were not shared for this illustrative case, so no confidential patient information is reproduced here. They are listed because they are the documents that support a real LEMS care plan, and each one answers a specific clinical question. In an actual patient record, the home care team would review these documents together before building the plan.

Table 8. Supporting documents and their role in care
DocumentWhat it confirmsHow it informs home care
Consultation / discharge summaryConfirmed diagnosis, treatment direction and follow-up planDefines the medication schedule, warning signs and review dates
Nerve conduction and EMG reportLocalised the defect to the neuromuscular junctionConfirms the neurological basis of weakness and supports realistic functional goals
Antibody test reportSupported an immune-mediated mechanismGuides expectations around immune-modifying therapy where used
Chest imaging reportParaneoplastic screening statusDetermines the urgency and frequency of oncology follow-up
PrescriptionsMedicines, doses and timingForms the basis of the home medication record and side-effect monitoring
Progress notesChanges in strength, autonomic symptoms and toleranceUsed to adjust the daily schedule and decide when to escalate
Confidentiality: No identifying details, laboratory values, imaging measurements or free-text clinical notes from a real patient are presented in this case study. The patient is fictional and the documents above are described by type and purpose only.

10Recovery Outcome

Functional outcome across the domains the home plan targeted.

The outcome is reported across the same domains the care plan was built around. The framing is deliberately measured: the goal of home healthcare in LEMS is safety, coordination and comfort, and the follow-up reflects that.

  • Mobility: transfers and stair use became safer with supervised technique, a walking aid and stable seating. Walking endurance improved modestly with rest pacing. Independence was preserved within safe limits rather than expanded unrealistically.
  • Pain: pain is not a primary feature of LEMS and was not reported as a problem in this case. No pain intervention was required.
  • Nutrition: meals were taken seated and comfortably despite dry mouth, supported by regular sips of water and a meal routine that avoided prolonged standing.
  • Medical stability: remained stable for home care through the follow-up period, with no falls recorded and no emergency visits triggered by the plan itself.
  • Family feedback: the family reported that the routine became easier to manage and that they felt more confident recognising symptoms that needed medical attention.
  • Remaining challenges: fluctuating leg weakness, postural dizziness, autonomic symptoms and the need for ongoing malignancy surveillance remain. Long-term outcomes depend on the underlying cause and the response to specialist treatment.
  • Long-term care: continued fall prevention, medication coordination, autonomic and swallowing or breathing monitoring, specialist follow-up, and family education remain in place as an ongoing plan rather than a finished episode.
Honest framing: This outcome describes improved care coordination and safety, not a cure. LEMS is typically a chronic, fluctuating condition. The value of home healthcare here is that it kept the patient safe, kept the neurologist’s plan running correctly every day, and gave the family the confidence to manage a rare and unfamiliar illness at home.

11Key Clinical Learnings

Specific insights from this case, not generic advice.

  1. Proximal leg weakness plus autonomic symptoms is a neuromuscular pattern, not ageing. When leg weakness is paired with dry mouth, constipation, reduced sweating or postural dizziness, the combination should prompt neurological evaluation rather than reassurance about getting older.
  2. Reduced reflexes are a useful clue. Reflexes that are diminished at rest and briefly augment after sustained contraction point toward LEMS and away from myasthenia gravis, where reflexes are usually preserved.
  3. Paraneoplastic screening is part of the diagnosis, not an optional extra. Because LEMS can be associated with small-cell lung cancer, chest imaging and malignancy follow-up belong in the initial workup and in long-term surveillance.
  4. Fall prevention is the highest-value home intervention. In a stable LEMS patient, a single fall can cause injury that reverses months of progress. Seating height, handrails, supervised transfers and avoiding walking alone during weak periods matter more than any single medicine taken in isolation.
  5. Medication coordination prevents harm. Amifampridine timing and immune-modifying therapy require precise adherence and side-effect watching. A written medicine record and a rule against independent changes protect the patient.
  6. Autonomic symptoms deserve active management. Dry mouth and constipation are often under-treated in LEMS and erode quality of life even when weakness is controlled.
  7. Family education changes outcomes. A family that can recognise red-flag symptoms and knows when to escalate prevents delayed emergencies and reduces unnecessary hospital visits.
  8. Set realistic goals. The aim of home care in LEMS is safety, coordination and preserved function, not a dramatic recovery. Honest goal-setting keeps the plan credible and sustainable.

12Frequently Asked Questions

Medically accurate answers for patients, caregivers and clinicians.

1. What is Lambert-Eaton Myasthenic Syndrome?
LEMS is a rare neuromuscular disorder in which impaired nerve-to-muscle communication causes muscle weakness and other symptoms. It is autoimmune in nature and often involves antibodies against presynaptic voltage-gated calcium channels at the neuromuscular junction.
2. Why does LEMS cause leg weakness?
The condition affects the release of acetylcholine at the neuromuscular junction, making it harder for nerves to activate muscles effectively. Weakness typically begins in the proximal muscles of the hips and thighs, which is why standing from a chair and climbing stairs become difficult early.
3. Can LEMS be associated with cancer?
Yes. Some cases are associated with small-cell lung cancer, so specialist evaluation and appropriate follow-up, including chest imaging as clinically indicated, are important parts of management. Treating an associated cancer, when present, is also part of managing the neurological condition.
4. Is there treatment for LEMS?
Yes. Treatment may include medicines that improve nerve-to-muscle communication, such as amifampridine and pyridostigmine, and therapies that reduce abnormal immune activity. Medication selection and dosing require individual medical supervision and should never be changed independently.
5. Can home assistance help people with LEMS?
Yes. Mobility assistance, fall prevention, daily living support, medication coordination and autonomic symptom monitoring can help manage everyday challenges, reduce the risk of falls and medication errors, and support the family in recognising warning signs.
6. How is LEMS different from myasthenia gravis?
In LEMS the defect is presynaptic: weakness often improves briefly with repeated muscle use, reflexes are reduced, and autonomic symptoms such as dry mouth are common. In myasthenia gravis the defect is postsynaptic: weakness typically worsens with repeated use, reflexes are usually normal, and eye and facial weakness are more prominent early on.
7. What symptoms should make a family seek urgent medical advice?
Seek advice for rapid worsening of leg or general muscle weakness, repeated falls, increasing difficulty standing or walking, persistent dizziness or fainting, new swallowing difficulty, unexplained weight loss, and new or worsening breathing problems. Severe swallowing or breathing difficulty requires urgent medical attention.
8. Is LEMS inherited or contagious?
No. LEMS is not contagious and is not usually inherited in a simple pattern. Most cases are autoimmune, either occurring on their own or in association with an underlying cancer such as small-cell lung cancer.
9. Can physiotherapy cure LEMS?
Physiotherapy does not cure LEMS, because the underlying problem is immune-mediated nerve-to-muscle signalling. It is valuable for safe mobility, walking-aid selection, transfer technique and fall prevention, and it works alongside, not instead of, the neurologist’s medical treatment.
10. Why is home healthcare clinically appropriate for LEMS?
Once a patient is medically stable, the main risks are falls during transfers and stairs, medication errors, under-monitored autonomic symptoms, and delayed recognition of red flags such as swallowing or breathing difficulty. Structured home support addresses exactly these risks and keeps the specialist’s plan running correctly at home.

Speak with AtHomeCare

If you are supporting a family member with a neuromuscular condition in Gurgaon or Delhi NCR, our clinical team can help build a structured home care plan around your treating doctor’s advice.

Corporate Office
Unit No. 703, 7th Floor, ILD Trade Centre, D1 Block, Malibu Town, Sector 47, Gurgaon, Haryana 122018

Medical Disclaimer

Every patient is unique. Treatment decisions in Lambert-Eaton Myasthenic Syndrome, including the choice of medicine, dosing, immune-modifying therapy and cancer screening, must always be made by qualified healthcare professionals familiar with the individual case.

This case study is an illustrative, educational document based on a fictional patient. It does not describe a guaranteed response to treatment and is not a substitute for professional medical advice, diagnosis or care.

Emergency symptoms, including severe swallowing or breathing difficulty, fainting, rapid worsening of weakness or repeated falls, require immediate hospital care. Home healthcare complements, but does not replace, emergency medical services.

© 2026 AtHomeCare. Clinical case study for educational purposes. Patient details are fictional and illustrative.

Unit No. 703, 7th Floor, ILD Trade Centre, D1 Block, Malibu Town, Sector 47, Gurgaon, Haryana 122018 · 9910823218 · care@athomecare.in

Leave A Comment

All fields marked with an asterisk (*) are required